Search clinical trials for: PX0612

Total 12 results

VTBIO Co. LTD
ADM Korea Inc

Completed

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease (ADD)

Alzheimer's Disease

Korea, Republic of
Pharmabiotix Inc
University of Alberta

Completed

The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea

Canada
NeuroDerm Ltd.

Withdrawn

A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

Parkinson

Italy
NeuroDerm Ltd.

Active, not recruiting

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease (BeyoND)

Parkinson's Disease

United States, Spain, Austria, Czechia, France, Poland, Germany, Israel, Italy
NeuroDerm Ltd.

Completed

Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

Parkinson's Disease

Israel
Mediforum Ltd., Co.
LSK Global Pharma Services Co. Ltd.

Recruiting

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease (PM012-2b)

Mild Alzheimer Disease

Korea, Republic of
NeuroDerm Ltd.

Completed

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

Parkinson's Disease

United States, Israel, Italy, Austria
NeuroDerm Ltd.
Michael J. Fox Foundation for Parkinson's Research

Completed

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

Parkinson's Disease

Israel
NeuroDerm Ltd.

Withdrawn

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Parkinson's Disease

Israel
NeuroDerm Ltd.

Completed

A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

Parkinson's Disease

Israel
NeuroDerm Ltd.
Quotient Clinical

Completed

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

Parkinson's Disease

United Kingdom
NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom

3

Subscribe